Understanding Your Risk · Epidemiology
How Common Is Alzheimer’s—and What Do the Numbers Mean If You Carry APOE4?
By Brian Paquette, DO, MPH
The short answer
- Alzheimer’s becomes much more common with age. It is uncommon in the late 60s and common in the late 80s.
- APOE4 raises risk but does not decide anyone’s future. Many carriers never develop dementia, and the averages below do not predict what will happen to you.
- Most worldwide totals count all dementia, not Alzheimer’s alone. Alzheimer’s is the most common cause, but the headline numbers you see in the news usually include every type.
How common is it at your age?
This is the share of older Americans living with clinical Alzheimer’s disease, by age group:
| Ages 65–74 |
|
5% about 1 in 20 |
| Ages 75–84 |
|
14% about 1 in 7 |
| Ages 85 and older |
|
35% about 1 in 3 |
Source: Chicago Health and Aging Project, adjusted to the 2020 US Census (Rajan et al., Alzheimer’s & Dementia, 2021, DOI). Exact figures: 5.3%, 13.8% and 34.6%.
These are population averages. Each figure includes APOE4 carriers and non-carriers together, along with people who have very different blood pressure, education, sleep and health histories. They describe how common Alzheimer’s is in a group, not the risk of any one person in it.
What this means if you carry APOE4
1. Age remains a major part of the picture. For carriers and non-carriers alike, risk in your late 60s is a small fraction of risk in your late 80s. An APOE4 result shifts where you sit on that curve. It does not replace the curve.
2. Averages are not predictions. None of the numbers in this article is your personal risk. Carriers who reach old age without dementia are not rare, and why that happens is an active area of research.
3. All-cause dementia rates have fallen at a given age in several US and European populations. It is less clear whether Alzheimer’s disease itself has declined. The trend is encouraging, although these studies cannot tell an individual APOE4 carrier how much their own risk can change.
4. The familiar “three to four times” figure may not apply to you. That number for one copy of APOE4 comes mostly from people of European ancestry. Estimates are higher in East Asian cohorts and lower in Black and Hispanic cohorts. It is also a relative figure, which says nothing on its own about your absolute chance of developing the disease.
Your next step: if you have recently learned your APOE4 status, start here for a guided path through what the result means and what to do next. If you carry two copies, read I Have Two Copies of APOE4. Am I Going to Get Alzheimer’s?
For readers who want the evidence
You can stop here if you only wanted the practical answer. The sections below explain where these numbers come from, including worldwide projections, how often new cases arise at each age, and how figures differ between populations. They use more technical language.
A note on definitions
Most global figures describe all-cause dementia, not Alzheimer’s disease specifically. Vascular dementia, Lewy body disease, frontotemporal degeneration and mixed pathology also contribute, and many older adults have more than one. Large surveys usually diagnose clinically, without amyloid or tau biomarkers. Where a study reports Alzheimer’s disease specifically, I say so. China’s national survey shows how the two can differ: among adults aged 60 and older, age- and sex-adjusted prevalence was 6.0% for all-cause dementia and 3.9% for Alzheimer’s disease, or an estimated 15.07 million people with dementia, 9.83 million of them with Alzheimer’s (Jia et al., Lancet Public Health, 2020;5(12):e661–e671, DOI).
The worldwide picture
The Global Burden of Disease (GBD) 2019 analysis estimated that 57.4 million people worldwide were living with dementia in 2019, and projected 152.8 million by 2050 (GBD 2019 Dementia Forecasting Collaborators, Lancet Public Health, 2022, DOI). Almost all of that growth comes from more people living to older ages. Global age-standardised prevalence was projected to stay essentially flat (change 0.1%, uncertainty interval −7.5% to 10.8%). Women outnumbered men with dementia, with a female-to-male ratio of 1.69 in 2019. The projected growth is very uneven:
| Region (GBD 2019) | Projected change in cases, 2019–2050 |
| North Africa and the Middle East | +367% |
| Eastern sub-Saharan Africa | +357% |
| Western Europe | +74% |
| High-income Asia Pacific | +53% |
According to the investigators, population growth drives most of the increase in sub-Saharan Africa, and population ageing drives most of it in east Asia.
Prevalence by age
The age figures at the top of this article come from the Chicago Health and Aging Project, a population-based cohort of 10,342 participants. Prevalence of clinical Alzheimer’s disease was 5.3% (95% CI 4.9–5.7) at ages 65–74, 13.8% (13.1–14.5) at 75–84, and 34.6% (33.3–35.8) at 85 and older, or 11.3% of all adults 65 and older. The study estimated 6.07 million Americans with clinical Alzheimer’s disease in 2020, rising to 13.85 million by 2060 (Rajan 2021). A global meta-analysis found that age-specific prevalence varied relatively little between world regions (Prince et al., Alzheimer’s & Dementia, 2013, DOI).
New cases by age
Incidence, the rate of new cases each year, describes risk better than prevalence because it does not depend on how long people survive with the disease. Pooling seven population-based cohorts in the United States and Europe (49,202 people older than 65), all-cause dementia incidence rose from about 4 per 1,000 person-years at ages 65–69 to about 65 per 1,000 at ages 85–89, roughly a sixteenfold difference. Between cohorts, the youngest group ranged from 1.6 to 8.6 per 1,000 and the oldest from 42.2 to 97.0 (Wolters et al., Neurology, 2020, DOI). An earlier meta-analysis found that the rise in incidence slows at advanced ages but showed no sign that incidence falls (Gao et al., Archives of General Psychiatry, 1998, DOI).
Differences between populations
The table below combines community-based studies from several continents. Designs, age ranges and diagnostic criteria differ, so compare rows only within the same study.
| Population and study | Measure | Finding |
| Most world regions, adults 60+ (Prince 2013) | Dementia, age-standardised prevalence | 5–7% |
| Latin America (Prince 2013) | Same | 8.5% |
| Four sub-Saharan African regions (Prince 2013) | Same | 2–4% |
| China, adults 60+ (Jia 2020) | Alzheimer’s disease, age/sex-adjusted prevalence | 3.9% |
| Yoruba, Ibadan, Nigeria (Hendrie 2001) | Alzheimer’s disease, age-standardised annual incidence | 1.15% |
| African Americans, Indianapolis (Hendrie 2001) | Same protocol, same investigators | 2.52% |
The Indianapolis–Ibadan study is unusual: two communities on two continents, studied with identical methods by the same investigators. Annual Alzheimer’s incidence among Yoruba in Ibadan was less than half that of African Americans in Indianapolis (Hendrie et al., JAMA, 2001;285(6):739–747, DOI). Because the two populations have shared ancestry but very different environments and life experiences, the finding is consistent with an important role for non-genetic factors. The study cannot determine which factors caused the difference.
Within the United States, a study of 274,283 Kaiser Permanente members aged 64 and older, followed for 14 years, found clear differences in dementia incidence between self-identified groups (Mayeda et al., Alzheimer’s & Dementia, 2016, DOI):
| Group (self-identified) | Incidence per 1,000 person-years | 25-year cumulative risk from age 65 |
| African American | 26.6 | 38% |
| American Indian / Alaska Native | 22.2 | 35% |
| Latino | 19.6 | 32% |
| Pacific Islander | 19.6 | 25% |
| White | 19.3 | 30% |
| Asian American | 15.2 | 28% |
In the Chicago cohort, prevalence of clinical Alzheimer’s disease was 10.0% among non-Hispanic White adults, 14.0% among Hispanic adults and 18.6% among non-Hispanic Black adults aged 65 and older (Rajan 2021).
These are differences between groups, measured with social categories. They are not evidence that one group is biologically more vulnerable than another. Racial and ethnic categories in US data also track education, income, cardiovascular and metabolic disease, access to care and lifetime exposure to disadvantage, each of which affects dementia risk.
Women and men
In the Framingham Heart Study, the lifetime risk of dementia at age 45 was about 1 in 5 for women and 1 in 10 for men. Cumulative incidence was similar between the sexes; the gap in lifetime risk appeared only above age 85. The authors suggested that men who survive to those ages may be a selected, lower-risk group, because men with more cardiovascular disease die earlier (Chêne et al., Alzheimer’s & Dementia, 2015, DOI). Whether women have higher risk at a given age is not settled: the 1998 meta-analysis reported higher Alzheimer’s incidence in women (OR 1.56, 95% CI 1.16–2.10) but not higher all-cause dementia (OR 1.18, 95% CI 0.95–1.46), and the 2020 consortium analysis found similar incidence in men and women.
Falling rates at a given age
In Framingham, five-year dementia incidence fell by 22%, 38% and 44% across successive epochs from the late 1970s to the early 2010s, a decline seen only among people with at least a high school education (Satizabal et al., New England Journal of Medicine, 2016, DOI). Across seven US and European cohorts, incidence fell by 13% per calendar decade (95% CI 7%–19%) (Wolters 2020). The causes have not been fully identified. These declines are in all-cause dementia; the evidence that Alzheimer’s disease itself has declined is weaker. A meta-analysis of population-based cohorts found that dementia incidence fell with later birth years, but Alzheimer’s disease incidence did not (Gao et al., Journal of the American Geriatrics Society, 2019, DOI). The 2024 Lancet Commission attributes a large share of dementia worldwide to 14 potentially modifiable risk factors across the life course (Livingston et al., Lancet, 2024, DOI). The documented declines come mainly from high-income, largely European-ancestry cohorts, and they were not designed to show how much an individual APOE4 carrier’s risk can change.
APOE4 across populations
APOE ε4 raises risk in every population studied, but the size of the effect differs. In the largest multi-ancestry analysis to date (68,756 individuals), the odds ratio for Alzheimer’s disease with ε3/ε4 compared with ε3/ε3 decreased in a stepwise pattern (Belloy et al., JAMA Neurology, 2023, DOI):
| Group | ε3/ε4 — OR (95% CI) |
| East Asian | 4.54 (3.99–5.17) |
| Non-Hispanic White | 3.46 (3.27–3.65) |
| Non-Hispanic Black | 2.18 (1.90–2.49) |
| Hispanic | 1.90 (1.65–2.18) |
These are odds ratios, not percentages. An odds ratio of 3.46 does not mean a 346% risk. It compares people with ε3/ε4 with people with ε3/ε3 in research samples, and it cannot be multiplied by the percentages in the age table above to give anyone’s personal chance of developing Alzheimer’s.
The same study found higher risk in women with ε3/ε4 concentrated at ages 60 to 70 (OR 1.48, 95% CI 1.10–2.01 in White participants), replicated in a meta-analysis of Black and Hispanic participants.
An interpretation, not a settled explanation. Groups with a higher overall dementia burden in US data show a weaker ε4 effect. One possibility is that where risk from other causes is high, a single allele accounts for a smaller share of the relative difference. That is plausible, but it does not by itself explain why ε4 odds ratios differ across populations. In the Belloy analysis, global ancestry could not explain the weaker associations in Hispanic participants, and other work points to the genetic ancestry of the chromosomal segment surrounding APOE itself. Self-identified race and genetic ancestry are not the same thing, and studies that use racial categories cannot capture this distinction. The ancestry evidence is covered in detail in APOE ε4 Risk Is Not the Same in Every Population.
Methods and limitations
This is a narrative review, not a systematic one. Every figure is quoted from the cited peer-reviewed source and was checked against the source record. Most global estimates are modelled from surveys that diagnose dementia clinically without biomarkers, and they combine Alzheimer’s disease with other causes. Methods, age ranges and diagnostic thresholds differ between studies, so figures from different studies should not be compared directly. Differences in survival and access to diagnosis can make prevalence look lower where people with dementia die sooner or are never assessed. US group comparisons use self-identified race and ethnicity, which are poor proxies for genetic ancestry. This article is educational and is not a substitute for individual medical advice or genetic counselling.
